REGENSBURG, Germany -- (BUSINESS WIRE) -- Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity (Click here for video) — announced today the closing of the second tranche of a Series B financing. The company’s founder and CEO, Wolfgang Goetz, M.D., Ph.D., will be looking to meet with additional investors, including potential corporate partners, at the Cardiovascular Research Foundation’s “TVT 2014” meeting in Vancouver starting later this week.
The company has previously announced successful 6-month follow-up results for a pilot study of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ and, therefore, best TAVI system.
“The six-month clinical results are striking,” said principal investigator Prof. Dr. Christian Hengstenberg. A cardiologist at the German Heart Center, Munich, Germany, Prof. Dr. Hengstenberg. “Unlike the second-generation TAVI systems, the Trinity aortic valve is able to be positioned precisely or in fact repositioned, even after full implantation, in a safe manner. In our study, Trinity’s novel sealing cuff continues to provide outstanding results without PVL, which is an unacceptably frequent complication of TAVI(1). Equally important, the risk of atrio-ventricular (AV) block has been mitigated due to the supra-annular positioning of the Trinity valve.”
“A severe limitation of currently marketed TAVI systems is that they cannot be repositioned once fully implanted. On the other hand, Trinity is designed to solve this life-threatening issue and thereby potentially reduces the unwanted consequences of PVL and AV block,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon by training. “Once our Trinity valve is completely expanded and anchored above the annulus, a cardiologist can then fully assess the valve’s function to determine whether it needs to be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity, which is why we have positioned Trinity as a Third-Generation TAVI System. I will be attending the ‘TVT 2014’ meeting, and I look forward to meeting with those who are interested in learning more about Trinity,” said Dr. Goetz.
About Transcatheter Technologies GmbH
Transcatheter Technologies GmbH is a privately held medical device company founded in 2009 and headquartered in Regensburg, Germany. The Trinity aortic valve prosthesis is comprised of a bovine pericardium valve with porcine pericardium-sealing cuff that is mounted on a self-expanding Nitinol frame. The Trinity aortic valve prosthesis is pre-mounted on a detachable catheter tip. Trinity’s unique features enable controlled positioning and true repositioning without foreshortening. The valve prosthesis is protected during folding of the stent. This Zero Pressure CrimpingTM is expected to improve valve durability and broaden the application of transcatheter valve implantations across a larger patient population.
(1) J Am Coll Cardiol. 2013 Mar 19;61(11):1125-36. doi: 10.1016/j.jacc.2012.08.1039. Epub 2013 Jan 30. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. Généreux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, van Mieghem NM, Alu MC, Serruys PW, Kappetein AP, Leon MB.
All information contained in this document derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this document or its contents. This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. International investors acknowledge risks in connection with political and economic uncertainties in foreign countries as well as currency risks. Persons who are in possession of this document are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends, or circumstances after the date of this press release.